ABVC BioPharma, Inc. (ABVC)
- Previous Close
1.0600 - Open
1.0300 - Bid 0.7344 x 200
- Ask 1.3100 x 200
- Day's Range
1.0200 - 1.0300 - 52 Week Range
0.4000 - 1.4000 - Volume
33,946 - Avg. Volume
688,706 - Market Cap (intraday)
16.094M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date May 15, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
www.abvcpharma.comRecent News: ABVC
View More
Performance Overview: ABVC
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVC
View MoreValuation Measures
Market Cap
16.41M
Enterprise Value
18.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.82
Price/Book (mrq)
13.38
Enterprise Value/Revenue
36.36
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.38%
Return on Equity (ttm)
-531.91%
Revenue (ttm)
509.59k
Net Income Avi to Common (ttm)
-4.9M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
313.12k
Total Debt/Equity (mrq)
441.35%
Levered Free Cash Flow (ttm)
-975.09k